Weiss Multi-Strategy Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,000	Closed	-$760K	–	692
2019 Q2	$760K	Buy	+5,000	New	+$608K	0.02%	397
2015 Q2	–	Sell	-15,000	Closed	-$199K	–	521
2015 Q1	$199K	Sell	15,000 -70,100	-82%	-$934K	0.01%	404
2014 Q4	$1.23M	Buy	85,100 +55,000	+183%	+$931K	0.04%	259
2014 Q3	$635K	Buy	30,100 +11,300	+60%	+$255K	0.02%	426
2014 Q2	$560K	Sell	18,800 -51,200	-73%	-$1.62M	0.01%	506
2014 Q1	$1.68M	Buy	70,000 +25,000	+56%	+$637K	0.03%	383
2013 Q4	$917K	Buy	+45,000	New	+$1.34M	0.02%	458

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Weiss Multi-Strategy Advisers's SRPT Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 35,211 shares — an estimated $3.4M sold.

Weiss Multi-Strategy Advisers first reported a position in SRPT in Q2 2013 and held it in 28 quarters. The position peaked at $8.33M in Q2 2018. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 35,211 Sarepta Therapeutics shares in Q1 2024, an estimated $3.4M.
Weiss Multi-Strategy Advisers first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 28 quarters.
Weiss Multi-Strategy Advisers's Sarepta Therapeutics position peaked at $8.33M in Q2 2018.
414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.